Antibodies to delta sleep-inducing peptide in ultralow doses: effect on the behavior of male mice with anxiety and depressive syndrome.
Lipina. T V TV; Mikhnevich. N V NV; Epstein. O I OI
Key Findings
- Ultralow‑dose antibodies to DSIP produced a strong anxiolytic effect in mice
- The effect was most pronounced in mice with pre‑existing anxiety/depressive syndrome
- Behavioral changes were measured using elevated plus‑maze, partition, and forced‑swim tests
Practical Outcomes
- For biohackers, this suggests the DSIP pathway might influence anxiety, but the research is limited to mice and uses an unconventional antibody approach. No human dosing or safety data are available, so it’s not ready for direct self‑experimentation. More studies are needed before practical protocols can be developed.
Summary
A study in male mice found that giving tiny amounts of antibodies against the sleep‑related peptide DSIP reduced anxiety‑like behavior, especially in mice already showing anxiety and depression signs. The tests used standard anxiety and depression assays.
Abstract
We studied the effect of antibodies to delta sleep-inducing peptide in ultralow doses on the behavior of male mice with anxiety and depressive syndrome resulting from competitive interactions. The behavior of animals was studied in the elevated plus-maze, partition, and forced swimming tests. The preparation produced a strong anxiolytic effect, which was especially pronounced in animals with anxiety and depressive syndrome.
Study Information
pubmed
2003
10.1023/a:1024740426779